Pearl River, NY
Location: Orangetown and Clarkstown, Rockland County, NY
Pfizer Worldwide Research and Development area of focus: Vaccines
Manufacturing Capabilities: Antibody Drug Conjugates
In-market products supported:
- Prevnar 13®
Total acreage owned by Pfizer: approximately 330 acres
Developed land: approximately 22.9 acres
Number of buildings: 5
Number of colleagues: more than 800
One of Pfizer’s nine major R&D sites.
Vaccine Research and Development develops first-in-class and best-in-class vaccines against diseases of major public health importance that impact all ages and geographies. Colleagues have developed and manufactured vaccines for more than a century at the site. Today, Vaccine Research & Development is a fully integrated organization with responsibilities from the early-idea stage through clinical development, product registration and post-marketing commitments.
Major recent accomplishments include leading the research and development efforts that resulted in the licensure of Prevnar 13® and Trumenba™. The development of Prevnar 13® earned Pfizer scientists the Prix Galien USA award in 2011. A next generation vaccine is under development to protect against additional disease-causing serotypes of pneumococcal bacteria. Pneumococcal disease is a leading cause of vaccine-preventable death worldwide in children younger than five years. It encompasses a complex group of illnesses, including bacteremia/sepsis and meningitis. A new vaccine is also under development to help protect adolescents and young adults in the U.S. against meningococcal disease, an uncommon but serious and potential life-threatening disease.
Pearl River scientists are currently working to develop vaccines against other major infectious diseases. Among the most advanced vaccine candidates under development at the site are maternal vaccines to confer protective antibodies to newborns against Group B Streptococcus (GBS) and Respiratory Syncytial Virus (RSV). GBS is the leading cause of dangerous infection in a newborn’s first week of life, including sepsis (blood infection) and meningitis. RSV is a common respiratory virus that affects the lungs and airways, with significant impact on young children and older adults.
Another innovative Vaccine R&D projects at the site is aimed at protecting against infections caused by Clostridioides difficile, which can include life-threatening diarrhea and pseudomembranous colitis.
The Pearl River site is the primary research and development center housing activities relating to Pfizer’s collaboration with BioNTech, which is focused on developing a potential mRNA-based coronavirus vaccine aimed at preventing COVID-19 infection.
The research and development work being done at the site today is continuing more than a century of innovation that has had life-changing impact around the world, from immunizing children against deadly infectious diseases to developing potential breakthrough therapies for leukemia. Its legacy of innovation dates back to 1907, when Dr. Ernst Lederle established the Pearl River site to produce antiserum to treat children with diphtheria in New York City. Since then, the site has developed vaccines to prevent diseases like smallpox and polio.